An All-Oral Breast Cancer Combination Wins Full FDA Approval

Full Approval for Inluriyo + Verzenio

FDA granted full approval for an all-oral regimen containing its estrogen receptor antagonist Inluriyo and kinase inhibitor Verzenio as a late-line option for breast cancer. Specifically, the approval clears the combo for adults with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2-negative (HER2-) breast cancer with an ESR1 mutation whose disease has progressed following one or more lines of prior endocrine therapy.

Eli Lilly on Friday announced that the U.S. FDA granted full approval for an all-oral regimen containing its estrogen receptor antagonist Inluriyo and kinase inhibitor Verzenio as a late-line option for breast cancer, on September 18, 2026.

What the Two Drugs Do

Inluriyo blocks estrogen's signal in certain breast cancer cells and helps break down the receptor that receives that signal, according to the drug's FDA-approved prescribing information. Verzenio blocks two proteins, CDK4 and CDK6, that can help cancer cells grow and divide. Verzenio first won FDA approval in 2017, and Inluriyo was approved as a stand-alone treatment in September 2025.

The all-oral combination of Inluriyo and Verzenio gives patients a treatment approach that targets the two central drivers of ER+ breast cancer, with an established tolerability profile and no new monitoring required.

EMBER-3 Data: Doubling PFS

In the Phase 3 EMBER-3 trial, Inluriyo in combination with Verzenio doubled median progression-free survival compared to standard endocrine therapy. Inluriyo in combination with Verzenio doubled median PFS, data that supported conversion from accelerated to full approval.

FDA approval for Inluriyo, an oral estrogen receptor antagonist, in combination with Verzenio for adults with ER+, HER2–, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy, was based on Phase 3 EMBER-3 data.

Why ESR1 Mutation Matters

ESR1 mutations emerge under aromatase inhibitor pressure and cause resistance to traditional endocrine therapy. The oral SERD class degrades mutant estrogen receptor, restoring endocrine sensitivity. This approval defines ESR1 testing as standard in second-line ER+ metastatic breast cancer, requiring circulating tumor DNA or tissue testing.

Split Decision: Lilly Wins Full, AstraZeneca Gets Conditional

Two weeks apart, the FDA split the oral SERD class in the one place that matters: the ESR1-mutated slice of hormone-receptor-positive breast cancer. On September 4, 2026, AstraZeneca won a conditional accelerated approval for camizestrant (Etcamah) in the first-line setting—a win its own FDA advisory panel had voted 6–3 against. On September 18, Eli Lilly converted imlunestrant (Inluriyo) into a full, unconditional approval as a combination with Verzenio.

Lilly wins full FDA nod for Inluriyo combo in breast cancer while AZN faces confirmatory trial requirements.

All-Oral Convenience and Tolerability

Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity. The FDA has granted full approval to Eli Lilly's Inluriyo for use alongside CDK4/6 inhibitor Verzenio in adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed on at least one prior line. The decision marks the second FDA approval for Inluriyo in under a year, following its 2025 clearance as standalone therapy.

The new all-oral regimen targets two key drivers of ER+ breast cancer while maintaining an established tolerability profile, which reinforces Eli Lilly's focus on broadening oncology options alongside its large diabetes/obesity franchise. No injections, no IV, no new monitoring required, a key quality-of-life advantage for metastatic patients.

Implications for Practice

Breast Cancer: FDA Approves New Oral Pill to Treat Common Mutation. For community oncologists, this offers an oral doublet after progression on first-line CDK4/6 plus aromatase inhibitor, delaying chemotherapy and preserving eligibility for antibody-drug conjugates like Enhertu. Testing for ESR1 mutation at progression is now actionable with full approval, not just accelerated.

Working Source Links:

Lilly wins full FDA approval for Inluriyo combo in breast cancer - https://www.tradingview.com/news/seekingalpha:c1c0845cf094b:0-lilly-wins-full-fda-approval-for-inluriyo-combo-in-breast-cancer/

U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for ER+, HER2-, ESR1-mutated advanced breast cancer - PRNewswire - https://www.prnewswire.com/news-releases/us-fda-approves-inluriyo-imlunestrant-in-combination-with-verzenio-abemaciclib-for-adults-with-er-her2-esr1-mutated-advanced-or-metastatic-breast-cancer-302883515.html

Breast Cancer: FDA Approves New Oral Pill to Treat Common Mutation - Healthline - https://www.healthline.com/health-news/fda-approves-eli-lilly-oral-combo-drug-common-breast-cancer-mutation

AstraZeneca failed where Lilly won: what the oral SERD split means for AZN and LLY in ESR1m breast cancer - https://www.ainvest.com/news/astrazeneca-failed-lilly-won-oral-serd-split-means-azn-lly-esr1m-breast-cancer-2609/

Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity - https://www.pharmtech.com/view/inluriyo-verzenio-combo-doubles-pfs-adds-oral-oncology-complexitySplit Decision: Lilly Wins Full, AstraZeneca Gets Conditional